Buplerum (Bupleurum chinense)

Bupleurum (Bupleurum chinense) is a traditional Chinese medicinal herb whose primary bioactive compounds, saikosaponins (particularly saikosaponin-a and saikosaponin-d), drive its hepatoprotective and anti-inflammatory effects. These triterpenoid saponins modulate glucocorticoid receptor activity and suppress NF-κB signaling, reducing inflammatory cytokine production and oxidative liver damage.

Origin & History

Bupleurum chinense, also known as Chai Hu, is a perennial herb from the Apiaceae family native to East Asia, particularly China. Its dried root, Radix Bupleuri, is harvested for medicinal use through methods like solvent fractionation, ensuring the extraction of active compounds.

Historical & Cultural Context

Bupleurum chinense has been used in Traditional Chinese Medicine for over 2,000 years, primarily to treat fevers, liver disorders, and digestive issues. It is also a key component in Japanese Kampo medicine for liver conditions.

Health Benefits

• May reduce liver cancer risk when used in formulas like sho-saiko-to, though effects are not solely attributable to bupleurum [Preliminary evidence]. • Exhibits hepatoprotective effects in animal models, such as reduced ALT/AST levels in CCl4-induced liver injury [Preclinical study]. • Demonstrates anti-inflammatory properties through cytokine modulation [Preclinical study]. • Inhibits certain liver cancer cell growth in vitro [In-vitro study]. • Traditional use suggests benefits for liver disorders and immune modulation [Historical use].

How It Works

Saikosaponin-a and saikosaponin-d, the principal triterpenoid glycosides in Bupleurum chinense, bind glucocorticoid receptors to potentiate endogenous cortisol-like anti-inflammatory activity without directly acting as steroids. These compounds also inhibit NF-κB and MAPK signaling pathways, suppressing downstream production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. Additionally, saikosaponins upregulate Nrf2-mediated antioxidant enzymes such as superoxide dismutase and glutathione peroxidase, protecting hepatocytes from oxidative stress-induced apoptosis.

Scientific Research

Clinical evidence for Bupleurum chinense is primarily derived from its inclusion in multi-herb formulas like sho-saiko-to, with no standalone randomized controlled trials identified. The available studies are preliminary and focus on animal models or mixed formulations.

Clinical Summary

Most human evidence for bupleurum comes from multi-herb Japanese Kampo formula sho-saiko-to (TJ-9), in which bupleurum is a principal ingredient; a randomized controlled trial in 260 cirrhotic patients found reduced hepatocellular carcinoma incidence over 5 years, though the effect cannot be isolated to bupleurum alone. Animal studies using CCl4-induced liver injury models consistently show significant reductions in serum ALT and AST levels with bupleurum extracts standardized to saikosaponins, indicating hepatoprotective activity at the preclinical level. Small pilot studies in humans with chronic hepatitis B suggest improvement in liver enzyme profiles, but sample sizes rarely exceed 50 participants and methodological quality is generally low. Overall, the evidence is preliminary to moderate for hepatoprotection; robust, large-scale placebo-controlled trials isolating bupleurum are lacking.

Nutritional Profile

Bupleurum chinense root (the primary medicinal part) contains minimal conventional macronutrients as it is used in small therapeutic doses (3–12g dried root per day in TCM practice), not as a food source. Key bioactive compounds include: Saikosaponins (triterpene saponins) — primarily saikosaponin-a, saikosaponin-b1, saikosaponin-b2, saikosaponin-c, and saikosaponin-d, collectively comprising approximately 0.3–2.2% of dry root weight, with saikosaponin-a and saikosaponin-d considered the most pharmacologically active; Polysaccharides (bupleuran 2IIb and related fractions) — approximately 3–8% of dry weight, contributing to immunomodulatory effects; Flavonoids — including rutin, isorhamnetin, and quercetin derivatives, present at trace concentrations (<0.1% dry weight); Volatile essential oils — approximately 0.1–0.5% dry weight, containing compounds such as 2-methyl cyclopentanone and bornyl acetate; Lignans — including bupleurumlignans at trace levels; Sterols — including alpha-spinasterol and stigmasterol at minor concentrations. Minerals present in dried root include small amounts of potassium, calcium, and magnesium, though concentrations are not standardized in the literature and are clinically insignificant at therapeutic doses. Crude fiber content is approximately 20–30% of dry weight typical of woody roots. Protein content is low, approximately 5–8% dry weight. Bioavailability note: Saikosaponins undergo significant hydrolysis in the gastrointestinal tract to their prosapogenin forms (e.g., saikosaponin-b2 from saikosaponin-a), which may be the primary absorbed species; water decoction (as used in TCM) extracts saikosaponins and polysaccharides effectively, while ethanolic extraction yields higher saikosaponin concentrations. First-pass hepatic metabolism significantly affects systemic bioavailability of saikosaponins.

Preparation & Dosage

Clinically studied dosages are from sho-saiko-to formulas containing Bupleurum chinense at 2.5 grams of the formula three times daily, providing approximately 400 mg of bupleurum per dose. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ginseng, Scullcap, Licorice, Ginger, Dandelion

Safety & Interactions

Bupleurum is generally well tolerated at typical doses of 3–12 g dried root per day in TCM decoctions or 300–600 mg standardized extract, but high doses may cause nausea, vomiting, and sedation. Saikosaponins have demonstrated immunostimulatory properties in vitro, raising a theoretical concern for exacerbation of autoimmune conditions such as lupus or rheumatoid arthritis, though clinical documentation is limited. Bupleurum may potentiate the sedative effects of CNS depressants and interact with immunosuppressants like cyclosporine due to CYP3A4 modulation by saikosaponins. It is contraindicated during pregnancy due to potential uterine-stimulating effects observed in animal models, and safety during breastfeeding has not been established.